Literature DB >> 7852346

The soluble exoplasmic domain of the type II transforming growth factor (TGF)-beta receptor. A heterogeneously glycosylated protein with high affinity and selectivity for TGF-beta ligands.

H Y Lin1, A Moustakas, P Knaus, R G Wells, Y I Henis, H F Lodish.   

Abstract

The transforming growth factor (TGF)-beta type II receptor is a transmembrane serine/threonine kinase which is essential for all TGF-beta-induced signals. In several cell types TGF-beta 2 is as potent as TGF-beta or TGF-beta 3 in inducing cellular responses, yet TGF-beta 2 does not bind to the majority of expressed type II receptors. Here we characterized the properties of the soluble extracellular domain of the human TGF-beta type II receptor synthesized in COS-7 cells. Like the membrane-attached type II receptor, the soluble receptor contains complex N-linked oligosaccharides as well as additional sialic acid residues that cause it to migrate heterogenously upon SDS-polyacrylamide gel electrophoresis. 125I-TGF-beta 1 binds to and is chemically cross-linked to this protein. Unlabeled TGF-beta 1 inhibits the binding of 125I-TGF-beta 1 with an apparent dissociation constant (Kd) of approximately 200 pM, similar to the apparent Kd (approximately 50 pM) of the cell-surface type II receptor. TGF-beta 3 inhibits the binding of 125I-TGF-beta 1 to the soluble type II receptor with a similar dissociation constant, approximately 500 pM. In contrast, 125I-TGF-beta 2 cannot bind and be chemically cross-linked to the soluble type II receptor, nor does as much as a 125-fold excess of unlabeled TGF-beta 2 inhibit the binding of 125I-TGF-beta 1 to the soluble receptor. This is the first demonstration of the binding affinities of the type II receptor in the absence of the other cell-surface molecules known to bind TGF-beta. Expressed alone in COS-7 cells the type II receptor also cannot bind TGF-beta 2; co-expression of type III receptor enables the type II receptor to bind TGF-beta 2. Thus, the type III receptor or some other component is required for transmission of TGF-beta 2-induced signals by the type II receptor.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7852346     DOI: 10.1074/jbc.270.6.2747

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  31 in total

1.  Reduction of bleomycin induced lung fibrosis by transforming growth factor beta soluble receptor in hamsters.

Authors:  Q Wang; Y Wang; D M Hyde; P J Gotwals; V E Koteliansky; S T Ryan; S N Giri
Journal:  Thorax       Date:  1999-09       Impact factor: 9.139

2.  NEU1 and NEU3 sialidase activity expressed in human lung microvascular endothelia: NEU1 restrains endothelial cell migration, whereas NEU3 does not.

Authors:  Alan S Cross; Sang Won Hyun; Alba Miranda-Ribera; Chiguang Feng; Anguo Liu; Chinh Nguyen; Lei Zhang; Irina G Luzina; Sergei P Atamas; William S Twaddell; Wei Guang; Erik P Lillehoj; Adam C Puché; Wei Huang; Lai-Xi Wang; Antonino Passaniti; Simeon E Goldblum
Journal:  J Biol Chem       Date:  2012-03-08       Impact factor: 5.157

3.  The crystal structure of TGF-beta 3 and comparison to TGF-beta 2: implications for receptor binding.

Authors:  P R Mittl; J P Priestle; D A Cox; G McMaster; N Cerletti; M G Grütter
Journal:  Protein Sci       Date:  1996-07       Impact factor: 6.725

4.  Type I (RI) and type II (RII) receptors for transforming growth factor-beta isoforms are expressed subsequent to transforming growth factor-beta ligands during excisional wound repair.

Authors:  L I Gold; J J Sung; J W Siebert; M T Longaker
Journal:  Am J Pathol       Date:  1997-01       Impact factor: 4.307

5.  Type III TGF-beta receptor-independent signalling of TGF-beta2 via TbetaRII-B, an alternatively spliced TGF-beta type II receptor.

Authors:  D Rotzer; M Roth; M Lutz; D Lindemann; W Sebald; P Knaus
Journal:  EMBO J       Date:  2001-02-01       Impact factor: 11.598

6.  Enhanced activity of transforming growth factor β1 (TGF-β1) bound to cartilage oligomeric matrix protein.

Authors:  Dominik R Haudenschild; Eunmee Hong; Jasper H N Yik; Brett Chromy; Matthias Mörgelin; Kaylene D Snow; Chitrangada Acharya; Yoshikazu Takada; Paul E Di Cesare
Journal:  J Biol Chem       Date:  2011-09-22       Impact factor: 5.157

7.  In vivo inhibition of rat stellate cell activation by soluble transforming growth factor beta type II receptor: a potential new therapy for hepatic fibrosis.

Authors:  J George; D Roulot; V E Koteliansky; D M Bissell
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-26       Impact factor: 11.205

8.  Alpha-smooth muscle actin expression upregulates fibroblast contractile activity.

Authors:  B Hinz; G Celetta; J J Tomasek; G Gabbiani; C Chaponnier
Journal:  Mol Biol Cell       Date:  2001-09       Impact factor: 4.138

9.  Different domains regulate homomeric and heteromeric complex formation among type I and type II transforming growth factor-beta receptors.

Authors:  Maya Mouler Rechtman; Alex Nakaryakov; Keren E Shapira; Marcelo Ehrlich; Yoav I Henis
Journal:  J Biol Chem       Date:  2009-01-15       Impact factor: 5.157

10.  Reconstitution of a pentameric complex of dimeric transforming growth factor beta ligand and a type I, II, III receptor in baculoviral-infected insect cells.

Authors:  K Matsuzaki; M Kan; W L McKeehan
Journal:  In Vitro Cell Dev Biol Anim       Date:  1996-06       Impact factor: 2.416

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.